Loading...
Indian Pharmaceutical Exporter · #9 for Ceftriaxone · $6.7M export value · DGFT Verified
Cipla Limited is the #9 Indian exporter of Ceftriaxone with $6.7M in export value and 266 verified shipments. Cipla Limited holds a 2.3% market share in Ceftriaxone exports across 5 countries. The company exports 98 pharmaceutical products worth $1.1B across 26 therapeutic categories.
| $51.1K |
| 3 |
| 0.8% |
| GUINEA | $25.6K | 1 | 0.4% |
Cipla Limited exports Ceftriaxone to 6 countries. The largest destination is YEMEN, DEMOCRATIC accounting for 49.2% of Cipla Limited's Ceftriaxone shipments, followed by YEMEN (30.1%) and YEMEN DEMOCRATIC (18.3%). These destinations reflect Cipla Limited's established distribution network and regulatory approvals in key markets.
| Buyer | Country | Value | Orders |
|---|---|---|---|
| AL JABAL DRUGS & MEDICAL APPLIANCES | YEMEN, DEMOCRATIC | $3.6M | 168 |
| AL JABAL DRUGS MEDICAL APPLIANCE | YEMEN DEMOCRATIC | $810.4K | 27 |
| AL JABAL GROUP FOR TRADE INVESTMENT | YEMEN | $721.3K | 19 |
| AL JABAL DRUGS & MEDICAL APPLIANCE | YEMEN | $665.0K | 21 |
| ALJABAL DRUGS AND MEDICAL APPLIANCE | YEMEN | $516.6K | 16 |
| PLANET PHARMA, | FRANCE | $55.1K | 2 |
| AL-JABAL GROUP FOR TRADE INVESTMENT | YEMEN, DEMOCRATIC | $54.2K | 2 |
| ALJABAL DRUGS MEDICAL APPLIANCES | YEMEN | $53.3K | 3 |
| ROZ LOGISTICS | TURKEY | $51.1K | 3 |
| AL-JABAL DRUGS MEDICAL APPLIANCES | YEMEN | $43.1K | 1 |
Cipla Limited supplies Ceftriaxone to 12 buyers globally. The largest buyer is AL JABAL DRUGS & MEDICAL APPLIANCES (YEMEN, DEMOCRATIC), followed by AL JABAL DRUGS MEDICAL APPLIANCE (YEMEN DEMOCRATIC) and AL JABAL GROUP FOR TRADE INVESTMENT (YEMEN). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
India exported $98.3M worth of Ceftriaxone through 11,257 shipments from 850 suppliers to 162 countries, serving 2,555 buyers globally. Cipla Limited contributes $6.7M to this total, accounting for 2.3% of India's Ceftriaxone exports. Cipla Limited ships Ceftriaxone to 6 countries through 12 buyers.
Cipla Limited's average Ceftriaxone shipment value is $25.0K per consignment, based on 266 shipments totaling $6.7M. The largest destination is YEMEN, DEMOCRATIC (49.2% of Cipla Limited's Ceftriaxone exports).
Cipla Limited ranks #9 among 850 Indian Ceftriaxone exporters with a 2.3% market share. The top 3 exporters are INNOVA CAPTAB LIMITED ($30.0M), AUROBINDO PHARMA LTD ($9.2M), CIPLA LIMITED ($6.7M). Cipla Limited processed 266 shipments to 5 destination countries.
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| CIPLACEF 1000 INJECTION 1GM (CEFTRIAXONESODIUM INJECTION POWDER 1000MG) | $1.2M | 43 |
| CIPLACEF 1000 INJECTION 1 GM CEFTRIAXONE SODIUM INJECTION POWDER 1000 MG | $721.3K | 19 |
| CIPLACEF 1000 INJECTION 1GM (CEFTRIAXONESODIUM INJECTION POWDER 1000MG)NOS | $668.7K | 54 |
| CIPLACEF 1000 INJECTION 1 GM (CEFTRIAXONE SODIUM INJECTION POWDER 1000 MG) . | $607.9K | 14 |
| CIPLACEF 500 INJECTION CEFTRIAXONE SODI | $445.9K | 14 |
| CIPLACEF 500 INJECTION (CEFTRIAXONE SODI | $280.0K | 8 |
| CIPLACEF 1000 INJECTION 1 GM (CEFTRIAXONE SODIUM INJECTION POWDER 1000 MG)NOS | $210.9K | 12 |
| CIPLACEF 1000 INJECTION 1GM CEFTRIAXONE SODIUM INJECTION POWDER 1000MG 1 X 1 GM WFI | $207.6K | 7 |
| CIPLACEF 1000 INJECTION 1GM (CEFTRIAXONE SODIUM INJECTION POWDER 1000MG) 1 X 1 GM + WFI | $198.1K | 6 |
| CIPLACEF 1000 INJECTION 1 GM CEFTRIAXONE SODIUM INJECTION POWDER 1000 MG 1 X 1 GM WFI | $179.7K | 6 |
Cipla Limited exports 43 distinct Ceftriaxone formulations including tablets, capsules, syrups, and combination drugs. The top formulation is CIPLACEF 1000 INJECTION 1GM (CEFTRIAXONESODIUM INJECTION POW with 43 shipments worth $1.2M.
Exporters ranked immediately above and below #9 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 1 | INNOVA CAPTAB LIMITED | $30.0M | 600 | 20 | $50.0K |
| 4 | AUROBINDO PHARMA LTD | $9.2M | 184 | 6 | $50.0K |
| 9 | CIPLA LIMITED ★ | $6.7M | 266 | 5 | $25.0K |
| 10 | THEON PHARMACEUTICALS LIMITED | $6.3M | 503 | 14 | $12.6K |
| 11 | SCOTT EDIL PHARMACIA LIMITED | $5.7M | 218 | 30 | $26.2K |
Cipla Limited ranks #9 among 850 Indian Ceftriaxone exporters. Average shipment value of $25.0K compared to the market average of $115.6K. The closest competitors by value are INNOVA CAPTAB LIMITED and AUROBINDO PHARMA LTD.
| Port | Shipments | % Share |
|---|---|---|
| NHAVA SHEVA SEA (INNSA1) | 1,199 | 10.7% |
| JNPT/ NHAVA SHEVA SEA | 819 | 7.3% |
| JNPT | 675 | 6.0% |
| SAHAR AIR CARGO ACC (INBOM4) | 547 | 4.9% |
| DELHI AIR CARGO ACC (INDEL4) | 472 | 4.2% |
| MUNDRA SEA | 460 | 4.1% |
| DELHI AIR | 457 | 4.1% |
| SAHAR AIR | 451 | 4.0% |
Cipla's export operations are currently navigating a complex geopolitical landscape. The Israel-Iran conflict has led to disruptions in Red Sea shipping routes, resulting in increased freight costs and extended transit times. These challenges are particularly acute for time-sensitive pharmaceutical shipments, necessitating strategic adjustments in logistics and supply chain management.
In the United States, recent import policies, including the imposition of 100% tariffs on branded or patented pharmaceutical products effective October 2025, have introduced additional hurdles for Indian exporters. While generic drugs, a significant component of Cipla's portfolio, may be less affected, the overall trade environment demands vigilance and adaptability. Conversely, the India-European Union Free Trade Agreement, concluded in January 2026, offers a promising avenue for Cipla. The agreement aims to eliminate tariffs on pharmaceuticals, potentially enhancing Cipla's competitiveness in the European market and offsetting challenges faced in other regions.
Maintaining stringent quality standards is paramount for Cipla, given the diverse regulatory environments across its export markets. The company has demonstrated a strong commitment to compliance, as evidenced by the U.S. Food and Drug Administration's (FDA) classification of its Bengaluru facility as Voluntary Action Indicated (VAI) in October 2025. This classification is crucial for sustaining and expanding Cipla's presence in the U.S. market. Additionally, the European Union's evolving regulatory framework, including the Falsified Medicines Directive, necessitates continuous adaptation to ensure compliance and maintain market access.
Cipla Limited exports 98 products worth $1.1B. Beyond Ceftriaxone, top products include Fluticasone, Amlodipine, Salbutamol, Telmisartan, Salmeterol. View the complete Cipla Limited profile for full portfolio analysis.
Latest developments and market context
Detailed market intelligence for Ceftriaxone — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Verify manufacturer licensing and export certifications with the official agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 162+ countries, 2,555+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Cipla Limited's Ceftriaxone exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Cipla Limited
Full Company Profile →
98 products · $1.1B total trade · 26 categories
Access shipment-level records, pricing trends, and buyer contacts for Cipla Limited.
Request DemoView Pricing →Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Ceftriaxone. For current shipment-level data, contact TransData Nexus.